Amplified COPD Screening for Primary Care

At the 2023 American Thoracic Society International Conference a symposium focused on common comorbidities seen with COPD, their management, and research needs.

Findings of the BOREAS trial of patients with COPD and type 2 inflammation make dupilumab the first biologic to significantly reduce exacerbations by 30% vs placebo.

“Patients with COPD who have AMI are less aggressively treated than those without COPD," leading to higher in-hospital mortality and long-term mortality,” wrote authors.

Your daily dose of clinical news you may have missed.

Pain is a prominent symptom among persons with COPD yet management is not included in clinical guidelines and current research findings are vague, say study authors.

Dupilumab in patients with uncontrolled COPD reduced annual exacerbations by 30%, a statistically significant and clinically meaningful outcome and a first for a biologic.